65 research outputs found

    Heart rate from face videos under realistic conditions for advanced driver monitoring

    Get PDF
    Abstract The role of physiological signals has a large impact on driver monitoring systems, since it tells something about the human state. This work addresses the recursive probabilistic inference problem in time-varying linear dynamic systems to incorporate invariance into the task of heart rate estimation from face videos under realistic conditions. The invariance encapsulates motion as well as varying illumination conditions in order to accurately estimate vitality parameters from human faces using conventional camera technology. The solution is based on the canonical state space representation of an Itô process and a Wiener velocity model. Empirical results yield to excellent real-time and estimation performance of heart rates in presence of disturbing factors, like rigid head motion, talking, facial expressions and natural illumination conditions making the process of human state estimation from face videos applicable in a much broader sense, pushing the technology towards advanced driver monitoring systems.</jats:p

    Propensity Scoring after Multiple Imputation in a Retrospective Study on Adjuvant Radiation Therapy in Lymph-Node Positive Vulvar Cancer

    Get PDF
    Propensity scoring (PS) is an established tool to account for measured confounding in non-randomized studies. These methods are sensitive to missing values, which are a common problem in observational data. The combination of multiple imputation of missing values and different propensity scoring techniques is addressed in this work. For a sample of lymph node-positive vulvar cancer patients, we re-analyze associations between the application of radiotherapy and disease-related and non-related survival. Inverse-probability-of-treatment-weighting (IPTW) and PS stratification are applied after multiple imputation by chained equation (MICE). Methodological issues are described in detail. Interpretation of the results and methodological limitations are discussed

    p53 and p16 expression profiles in vulvar cancer:a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group

    Get PDF
    Background: There are 2 known pathways for tumorigenesis of vulvar squamous cell carcinoma—a human papillomavirus–dependent pathway characterized by p16 overexpression and a human papillomavirus–independent pathway linked to lichen sclerosus, characterized by TP53 mutation. A correlation of human papillomavirus dependency with a favorable prognosis has been proposed. Objective: The objective of the study was to further understand the role of human papillomavirus and p53 status in vulvar squamous cell carcinoma and characterize its clinical relevance. Study Design: The Arbeitsgemeinschaft Gynaecological Oncology Chemo and Radiotherapy in Epithelial Vulvar Cancer-1 study is a retrospective cohort study of 1618 patients with primary vulvar squamous cell carcinoma Fédération Internationale de Gynécologie et d'Obstétrique stage ≥1B treated at 29 gynecologic cancer centers in Germany between 1998 and 2008. For this translational substudy, formalin-fixed paraffin-embedded tissue was collected. A tissue microarray was constructed (n=652 samples); p16 and p53 expression was determined by immunohistochemistry. Human papillomavirus status and subtype were analyzed by polymerase chain reaction. Results: p16 immunohistochemistry was positive in 166 of 550 tumors (30.2%); p53 staining in 187 of 597 tumors (31.3%). Only tumors with available information regarding p16 and p53 immunohistochemistry and without p53 silent expression pattern were further analyzed (n=411); 3 groups were defined: p53+ (n=163), p16+/p53− (n=132), and p16−/p53− (n=116). Human papillomavirus DNA was detected in 85.6% of p16+/p53− tumors; human papillomavirus-16 was the most common subtype (86.3%). Patients with p16+ tumors were younger (64 vs 72 years for p53+, respectively, 69 years for p16−/p53− tumors; P<.0001) and showed lower rates of lymph-node involvement (28.0% vs 42.3% for p53+, respectively, 30.2% for p16−/p53− tumors; P=.050). Notably, 2-year-disease-free and overall survival rates were significantly different among the groups: disease-free survival, 47.1% (p53+), 60.2% (p16−/p53−), and 63.9% (p16+/p53−) (P<.001); overall survival, 70.4% (p53+), 75.4% (p16−/p53−), and 82.5% (p16+/p53−) (P=.002). In multivariate analysis, the p16+/p53− phenotype showed a consistently improved prognosis compared with the other groups (hazard ratio, 0.66; 95% confidence interval, 0.44–0.99; P=.042). Conclusion: p16 overexpression is associated with an improved prognosis whereas p53 positivity is linked to an adverse outcome. Our data support the hypothesis of a clinically relevant third subgroup of vulvar squamous cell carcinoma with a p53−/p16− phenotype showing an intermediate prognosis that needs to be further characterized

    Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

    Get PDF
    PURPOSEIn the ENGOT-OV16/NOVA trial (ClinicalTrials.gov identifier: NCT01847274), maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor, prolonged progression-free survival in patients with platinum-sensitive, recurrent ovarian cancer who had a response to their last platinum-based chemotherapy. The objective of the study was to assess the clinical benefit and patient-reported outcomes in patients who had a partial response (PR) and complete response (CR) to their last platinum-based therapy.PATIENTS AND METHODSA total of 553 patients were enrolled in the trial. Of 203 patients with a germline BRCA mutation (gBRCAmut), 99 had a PR and 104 had a CR to their last platinum-based therapy; of 350 patients without a confirmed gBRCAmut (non?gBRCAmut), 173 had a PR and 177 had a CR. Post hoc analyses were carried out to evaluate safety and the risk of progression in these patients according to gBRCAmut status and response to their last platinum-based therapy. Ovarian cancer?specific symptoms and quality of life were assessed using the Functional Assessment of Cancer Therapy?Ovarian Symptom Index.RESULTSProgression-free survival was improved in patients treated with niraparib compared with placebo in both the gBRCAmut cohort (PR: hazard ratio [HR], 0.24; 95% CI, 0.131 to 0.441; P < .0001; CR: HR, 0.30; 95% CI, 0.160 to 0.546; P < .0001) and the non?gBRCAmut cohort (PR: HR, 0.35; 95% CI, 0.230 to 0.532; P < .0001; CR: HR, 0.58; 95% CI, 0.383 to 0.868; P = .0082). The incidence of any-grade and grade 3 or greater adverse events was manageable. No meaningful differences were observed between niraparib and placebo in PR and CR subgroups with respect to patient-reported outcomes.CONCLUSIONPatients achieved clinical benefit from maintenance treatment with niraparib regardless of response to the last platinum-based therapy

    Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

    Get PDF
    Olaparib has shown significant clinical benefit as maintenance therapy in women with newly diagnosed advanced ovarian cancer with a mutation. The effect of combining maintenance olaparib and bevacizumab in patients regardless of mutation status is unknown. We conducted a randomized, double-blind, international phase 3 trial. Eligible patients had newly diagnosed, advanced, high-grade ovarian cancer and were having a response after first-line platinum-taxane chemotherapy plus bevacizumab. Patients were eligible regardless of surgical outcome or mutation status. Patients were randomly assigned in a 2:1 ratio to receive olaparib tablets (300 mg twice daily) or placebo for up to 24 months; all the patients received bevacizumab at a dose of 15 mg per kilogram of body weight every 3 weeks for up to 15 months in total. The primary end point was the time from randomization until investigator-assessed disease progression or death. Of the 806 patients who underwent randomization, 537 were assigned to receive olaparib and 269 to receive placebo. After a median follow-up of 22.9 months, the median progression-free survival was 22.1 months with olaparib plus bevacizumab and 16.6 months with placebo plus bevacizumab (hazard ratio for disease progression or death, 0.59; 95% confidence interval [CI], 0.49 to 0.72; P<0.001). The hazard ratio (olaparib group vs. placebo group) for disease progression or death was 0.33 (95% CI, 0.25 to 0.45) in patients with tumors positive for homologous-recombination deficiency (HRD), including tumors that had mutations (median progression-free survival, 37.2 vs. 17.7 months), and 0.43 (95% CI, 0.28 to 0.66) in patients with HRD-positive tumors that did not have mutations (median progression-free survival, 28.1 vs. 16.6 months). Adverse events were consistent with the established safety profiles of olaparib and bevacizumab. In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenance olaparib provided a significant progression-free survival benefit, which was substantial in patients with HRD-positive tumors, including those without a mutation. (Funded by ARCAGY Research and others; PAOLA-1 ClinicalTrials.gov number, NCT02477644.)

    Risk for pelvic metastasis and role of pelvic lymphadenectomy in node-positive vulvar cancer - results from the AGO-VOP.2 QS vulva study

    Get PDF
    Simple Summary In node-positive vulvar squamous cell cancer, questions of when and how to perform pelvic lymphadenectomy (LAE) as well as the optimal extent of pelvic treatment in general have been surrounded by considerable controversy. In Germany, systematic pelvic LAE is currently recommended as a staging procedure in patients at risk for pelvic nodal involvement in order to prevent morbidity caused by pelvic radiotherapy (RT) in patients without histologically-confirmed pelvic involvement. However, the population at risk for pelvic metastases remains insufficiently described, resulting in the potential overtreatment of a considerable proportion of patients with groin-positive disease. This applies to the indication to perform surgical staging but also to adjuvant RT of the pelvis without previous pelvic staging. Our study aims to describe the risk for pelvic lymph node metastasis with regard to positive groin nodes and to clarify the indication criteria for pelvic treatment in node-positive vulvar cancer. Abstract The need for pelvic treatment in patients with node-positive vulvar cancer (VSCC) and the value of pelvic lymphadenectomy (LAE) as a staging procedure to plan adjuvant radiotherapy (RT) is controversial. In this retrospective, multicenter analysis, 306 patients with primary node-positive VSCC treated at 33 gynecologic oncology centers in Germany between 2017 and 2019 were analyzed. All patients received surgical staging of the groins; nodal status was as follows: 23.9% (73/306) pN1a, 23.5% (72/306) pN1b, 20.4% (62/306) pN2a/b, and 31.9% (97/306) pN2c/pN3. A total of 35.6% (109/306) received pelvic LAE; pelvic nodal involvement was observed in 18.5%. None of the patients with nodal status pN1a or pN1b and pelvic LAE showed pelvic nodal involvement. Taking only patients with nodal status ≥pN2a into account, the rate of pelvic involvement was 25%. In total, adjuvant RT was applied in 64.4% (197/306). Only half of the pelvic node-positive (N+) patients received adjuvant RT to the pelvis (50%, 10/20 patients); 41.9% (122/291 patients) experienced recurrent disease or died. In patients with histologically-confirmed pelvic metastases after LAE, distant recurrences were most frequently observed (7/20 recurrences). Conclusions: A relevant risk regarding pelvic nodal involvement was observed from nodal status pN2a and higher. Our data support the omission of pelvic treatment in patients with nodal status pN1a and pN1b

    Nicht-intrusive Mimikanalyse

    No full text
    In the field of hardware development the new technical advances provide innovative human-computer- interfaces by increasing computing power. In particular the non-intrusive mimic analysis has a high potential useful for many application areas, as e.g. language recognition, special control or medical engineering. In the called areas it is desirable to extract the essential features of human face (head-pose, the location of eye-brows, the gaze, and mouth) contactless and to interpret them subsequently. For this task there are already different procedures which show a good recognition capacity, provided an idealized framework. Varying illumination conditions and complex image backgrounds are disregarded (not considered). An extensive training is often necessary as well. Various approaches require additional special hardware, as e.g. stereo cameras or infrared-radiator, to gain additional information thereby. The presented work deals with the development of a video-based recognition system for non-intrusive analysis of facial appearance, whereas only a notebook and a webcam are applied. Compared to the existent systems a higher independence will be achieved, concerning the environment and individual features of the user. This can particularly be guaranteed by the implementation of adaptive approaches combined with a biomechanical face model. Thereby the approaches applied work in the real time, so that first-time processing rate up to 40 images per second can be achieved on the standard hardware. The concept of this work is based on so-called Active Appearance Models, which combine statistical knowledge in respect of geometry and texture information. The adjustment of face-graphs correlates highly with the underlying training material. In the existing work for the generation of training date a biomechanical 3D head-model will first time be fit, which is only based on one users frontal view. This model makes possible to simulate synthetically different illumination circumstances and face expressions. The evaluation of the complete system was carried out in the context of video-based sign language recognition, because in that the non-manual features play a decisive role concerning the information transfer. Thereby promising results had been arisen, which could also be confirmed under real conditions in form of a special control system for wheelchairs

    Nicht-intrusive Mimikanalyse

    Get PDF
    In the field of hardware development the new technical advances provide innovative human-computer- interfaces by increasing computing power. In particular the non-intrusive mimic analysis has a high potential useful for many application areas, as e.g. language recognition, special control or medical engineering. In the called areas it is desirable to extract the essential features of human face (head-pose, the location of eye-brows, the gaze, and mouth) contactless and to interpret them subsequently. For this task there are already different procedures which show a good recognition capacity, provided an idealized framework. Varying illumination conditions and complex image backgrounds are disregarded (not considered). An extensive training is often necessary as well. Various approaches require additional special hardware, as e.g. stereo cameras or infrared-radiator, to gain additional information thereby. The presented work deals with the development of a video-based recognition system for non-intrusive analysis of facial appearance, whereas only a notebook and a webcam are applied. Compared to the existent systems a higher independence will be achieved, concerning the environment and individual features of the user. This can particularly be guaranteed by the implementation of adaptive approaches combined with a biomechanical face model. Thereby the approaches applied work in the real time, so that first-time processing rate up to 40 images per second can be achieved on the standard hardware. The concept of this work is based on so-called Active Appearance Models, which combine statistical knowledge in respect of geometry and texture information. The adjustment of face-graphs correlates highly with the underlying training material. In the existing work for the generation of training date a biomechanical 3D head-model will first time be fit, which is only based on one users frontal view. This model makes possible to simulate synthetically different illumination circumstances and face expressions. The evaluation of the complete system was carried out in the context of video-based sign language recognition, because in that the non-manual features play a decisive role concerning the information transfer. Thereby promising results had been arisen, which could also be confirmed under real conditions in form of a special control system for wheelchairs
    • …
    corecore